Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05249894 | Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy(LAM-SEPSIS) | unknown | — | 400 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05297123 | Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid | unknown | Phase 1 | 30 | First Affiliated Hospital Xi'an Jiaotong University |
| 1 |
| Mar 28, 2022 |
| clinicaltrials |
| NCT04375683 | Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL | unknown | Phase 3 | 28 | Zhongda HospitalOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT04490707 | Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML | unknown | Phase 3 | 60 | Ge ZhengOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 109 | Kartos Therapeutics, Inc.INDUSTRY | 8 | Mar 21, 2022 | clinicaltrials |
| NCT03251352 | TKI Discontinuation in CML Patients of China(TFR_china) | unknown | — | 98 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03942094 | Nilotinib for First-line Newly Diagnosed CML-CP Patients | unknown | Phase 3 | 100 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04677439 | Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | unknown | Phase 4 | 200 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04867928 | Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia | unknown | Phase 2 | 35 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04551235 | Establishing Automatic Method of Counting and Classify Bone Marrow and Peripheral Blood Cells | unknown | — | 900 | National Taiwan University HospitalOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT04604691 | Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD) | unknown | Phase 1 | 20 | Seoul National University HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04174612 | AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance(AMELIORATE) | unknown | Phase 3 | 172 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05262465 | Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML | unknown | N/A | 300 | guomeiOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04950777 | Feasibility and Efficacy of Physical Literacy Screening Integration Into Pediatric Clinical Settings(PLAY II) | unknown | N/A | 200 | Boston Children's HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05252572 | Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT02776605 | Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia(PONALFIL) | unknown | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05239689 | Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT03529227 | Gazyva Infusion Reaction Investigation(GAIRI) | unknown | — | 104 | Healthy FutureOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03647800 | Study of APVO436 in Patients With AML or MDS | unknown | Phase 1 | 136 | Aptevo Research and Development LLCINDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05233683 | Caudal Block Versus Dorsal Penile Nerve Block Plus Ring Block for Pain Management of Different Surgical Techniques of Circumcision in Infants and Children | unknown | Phase 3 | 120 | King Saud UniversityOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05223686 | To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05215015 | Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia | unknown | Early Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT05206045 | Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies(SURPASSe) | unknown | — | 700 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05206903 | Emotional and Physical Health Status of Adults | unknown | — | 250 | Pamukkale UniversityOTHER | 0 | Jan 25, 2022 | clinicaltrials |
| NCT05203809 | Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies(THERMAL) | unknown | — | 20 | Malaghan Institute of Medical ResearchOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT01358201 | PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years | unknown | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT01366898 | Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) | unknown | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT03412292 | MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04187495 | Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05137860 | Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD | unknown | Phase 4 | 56 | Hospital General de MexicoOTHER_GOV | 1 | Jan 18, 2022 | clinicaltrials |
| NCT05008575 | Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 27 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT01752062 | Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors(CML1012) | unknown | — | 148 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01761890 | Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib(CML1113) | unknown | — | 147 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT03751917 | Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia(APL0618) | unknown | — | 100 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT04640909 | Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients | unknown | N/A | 23 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05133310 | Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia | unknown | Phase 4 | 108 | Hospital General de MexicoOTHER_GOV | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05152537 | FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia(NTU-CML-001) | unknown | — | 15 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05175508 | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | unknown | Phase 2 / Phase 3 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05023707 | Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT05145101 | Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia(Pneumo-CLL) | unknown | — | 150 | Hannah Garcia GarridoOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT05164042 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT04722952 | PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML | unknown | Phase 3 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05127135 | Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies | unknown | Phase 1 | 30 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05127798 | RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old. | unknown | — | 50 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05123352 | Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies | unknown | — | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 17, 2021 | clinicaltrials |
| NCT04752527 | Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features | unknown | Phase 2 | 42 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04014894 | ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma | unknown | Phase 1 | 9 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 12, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2022source: clinicaltrials